Download Files:
Products Details
Product Description
– IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies[1].
Web ID
– HY-146697
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H27N7OS
References
– [1]Beilei Wang, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. Eur J Med Chem. 2020 Dec 1;207:112744.
CAS Number
– 2416844-79-4
Molecular Weight
– 473.59
SMILES
– O=C(NC1=NC(C)=C(C2=CC3=C(C=C2)C(/C=C/C4=NC=CC=C4)=NN3)S1)CN5CCN(C)CC5
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Bcr-Abl;c-Fms;c-Kit;PDGFR;Trk Receptor
Isoform
– Abl;PDGFRα;PDGFRβ;TrkA;TrkB;TrkC
Pathway
– Apoptosis;Neuronal Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
